Monday, December 20, 2021 2:50:52 PM
But a Covid EUA is coming. Virtually all currently authorized mAbs are useless against Omicron. Lenz has 154% efficacy for patients with CRP<150mg/l. Lenz is variant agnostic so it will have the same efficacy against Omicron as previous variants. Lenz is the most obvious way to treat newly hospitalized Omicron patients. While there is no guarantee that lenzilumab will get the EUA this winter, I think the chances are better that it will than won't.
So HGEN is a safe long term investment because of the the growing potential for GM-CSF inhibition but has a high chance of going 5x-20x in the next few months if lenz gets the Covid EUA. It is an easy choice to stay invested. I just went back to 100% invested in HGEN.
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM